Targaprimir-96 TFA

Targaprimir-96 TFA shows a dose-response in MDA-MB-231 triple negative breast cancer cells with an IC₅₀ of ~50 nM by assessing the reduction of mature miR-96 levels. Targaprimir-96 (50 nM) TFA boosts the amount of the pri-miRNA and decreases the levels of the pre-miRNA and mature miRNA in a dose-dependent manner^[1].
Targaprimir-96 TFA (50 nM; 48 hours) increases FOXO1 levels and triggers apoptosis in breast cancer cell line 4175^[1].
Targaprimir-96 TFA binds RNA3 (contains both the Drosha site and the adjacent 1×1 nt GG internal loop) with a K_d of 85 nM. Targaprimir-96 binds RNA1, RNA2, RNA4, and RNA5 with K_d values of 1.2, 0.9, 1.2, and 1.5 μM, respectively. Thus, Targaprimir-96 TFA is highly RNA-selective and recognizes both the 1×1 nt GG and 1×1 nt UU loops to provide high affinity, effectively discriminating against a variety of related targets^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.